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1ABSTRACT
Electro-hyperthermia inhibits glioma tumorigenicity through the 
induction of E2F1-mediated apoptosis
Jihye Cha
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Chang Geol Lee)
Purpose: Modulated electro-hyperthermia (mEHT), also known as 
oncothermia, shows remarkable treatment efficacies to various types of 
tumors, including glioma. The aim of the present study was to 
investigate the molecular mechanism underlying phenotypic changes in 
oncothermic cancer cells. 
Materials and methods: U87-MG and A172 human glioma cells were 
exposed to mEHT (42℃/60 min) three times with a 2-day interval and 
subsequently tested for growth inhibition using MTS, FACS and 
microscopic analysis. To obtain insights into the molecular changes in 
response to mEHT, global changes in gene expression were examined 
using RNA sequencing. For in vivo evaluation of mEHT, we used U87-
MG glioma xenografts grown in nude mice. 
2Results: mEHT inhibited glioma cell growth through the strong 
induction of apoptosis. The transcriptomic analysis of differential gene 
expression under mEHT showed that the anti-proliferative effects were 
induced through a subset of molecular alterations, including the 
upregulation of E2F1 and CPSF2 and the downregulation of ADAR 
and PSAT1. Subsequent Western blotting revealed that mEHT
increased the levels of E2F1 and p53 and decreased the level of PARP-
1, accelerating apoptotic signaling in glioma cells. mEHT significantly 
suppressed the growth of human glioma xenografts in nude mice. We 
also observed that mEHT dramatically reduced the portion of CD133+
glioma stem cell population and suppressed cancer cell migration and 
sphere formation. 
Conclusions: These findings suggest that mEHT suppresses glioma cell 
proliferation and mobility through the induction of E2F1-mediated 
apoptosis and might be an effective treatment for eradicating the brain 
tumors. 
--------------------------------------------------------------------------------------
Key words: electro-hyperthermia, glioma, E2F1, apoptosis, cancer stem 
cells
3Electro-hyperthermia inhibits glioma tumorigenicity through the 
induction of E2F1-mediated apoptosis
Jihye Cha
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Chang Geol Lee)
I. INTRODUCTION
Gliomas are the most common and deadly brain tumors, accounting for ~80% 
of the primary malignancies of the brain.1, 2 Despite recently advanced 
multimodal therapies, such as surgery, chemotherapy and radiotherapy, the 
overall 5-year survival rate for malignant glioma remains less than 10%.3
Thus, new approaches to improve the treatment efficacy are needed. 
Hyperthermia cancer therapy is currently used either for ablation purposes 
as an alternative to surgery or in combination with chemotherapy and/or 
radiation therapy to enhance the effects of those traditional therapies.4
Modulated electro-hyperthermia (mEHT) is a complementary treatment 
method effective against various types of tumors, including gliomas.5, 6 The 
principle of mEHT is based on the classical hyperthermia, but the difference is 
4that mEHT is physically designed to promote the direct absorption of the 
modulated radiofrequency current in the extracellular fluid. In mEHT, the 
extracellular liquid is heated, creating a slight temperature difference 
(1/1000℃) between the inner and outer temperature of the cell. As a result, 
the heat flows into the cell through the membrane until the temperature 
difference extinct, thereby destroying the membrane of the cancer cells.7-9
When combined with alkylating chemotherapy or the molecular targeting 
agent sorafenib, mEHT exhibits synergistic anti-cancer effects in clinical trials 
with glioma or hepatocellular carcinoma patients.10, 11 A recent study also 
showed that mEHT induces an abscopal effect, thereby enhancing the 
antitumor effects of immune-therapy.12
Although the anti-tumor efficacy of mEHT has been extensively studied in 
both laboratory and clinical settings, the underlying molecular mechanisms of 
this treatment are not yet clearly understood. In the present study, we aimed to 
elucidate the molecular mechanisms mediating the phenotypic changes in 
oncothermic tumor cells using a laboratory mEHT device for in vitro
experiments and a glioma xenograft model. We also performed RNA 
sequencing and subsequent protein analysis to understand the mechanism on a 
whole genome scale. We also performed experiments that detecting CD133+
glioma stem cells, cell migration assay, and sphere forming assay to 
investigate the effect of mEHT on the cancer stem cells.
5II. MATERIALS AND METHODS
1. Cell culture 
Human brain cancer cell lines, U87-MG and A172, were purchased from 
the Korean Cell Line Bank (KCLB, Seoul, South Korea). U87-MG and A172 
cells were cultured in MEM and RPMI-1640 medium, respectively, 
supplemented with 10% of fetal bovine serum (HyClone, South Logan, UT, 
USA) and 1% of penicillin/streptomycin solution (HyClone), at 37℃ with 5% 
CO2. The phenotypes of these cell lines have been authenticated by the KCLB.
2. Modulated electro-hyperthermia (mEHT) 
The LAB-EHY100 device (OncoTherm Ltd., Hungary) was used in in vitro
and in vivo mEHT treatment. To mimic clinical conditions, mEHT (3W power, 
42℃ for 60 min) was administered to glioma cells three times at 2-day 
intervals. During the 60 min of mEHT, the radio-frequency (RF) power level 
was controlled using the fluorotopic temperature measurement system 
(Luxton m3300; Lumasense, Santa Clara, CA, USA) to maintain the heating 
temperature at 42℃. For in vivo experiments, four-week old male BALB/c 
nude mice were purchased from Orientbio (Seongnam, South Korea). To 
elucidate the efficacy of mEHT against in vivo tumors, 1×107 U87-MG cells 
were injected into the right flanks of nude mice and the xenografts were 
treated with mEHT using the same instrumental conditions on 9, 11, 13, 15, 
617, 19 and 21 days after tumor cell injection. The tumor size was measured 
using a vernier caliper and calculated as (the minor axis2 × the major axis ×
1/2). 
3. Measurement of cell proliferation and apoptotic cell death 
The cell growth was measured using the CellTiter 96 Aqueous One 
Solution Cell Proliferation Assay (Promega, Madison, WI, USA) according to 
the manufacturer’s instructions. The cells were treated as described above and 
incubated for 2 hours at 37℃ in a humidified, 5% CO2 atmosphere. The 
colored formazan products were determined by measuring the absorbance at 
490 nm using a VersaMax microplate reader (Molecular Device, Sunnyvale, 
CA, USA). Annexin V and PI dual staining was used to detect apoptotic cells, 
but the cells were not fixed with 70% ethanol. Apoptotic cells were stained 
using the FITC Annexin V Apoptosis Detection Kit I (BD Pharmingen, San 
Jose, CA, USA) according to the manufacturer’s instructions. The cell death 
was measured through FACSVerse flow cytometry (BD Bioscience) and 
quantified using FlowJo software. The induction of apoptosis was also 
measured using the ApoStrand ELISA Apoptosis Detection Kit (Biomol 
International, Plymouth Meeting, PA, USA). This method detects denatured 
single-stranded DNA in apoptotic cells, but not in the necrotic cells or cells 
with DNA breaks. 
74. Clonogenic assay 
The effect of mEHT on the clonogenic survival of tumors was studied. The 
cells treated with mEHT were seeded onto 24-well culture plates at 1×103 
cells per well. The cells were maintained in culture for 12 days without 
medium change to let the viable cells propagate to sizable colonies for 
quantification. The colonies were fixed with methanol-acetic acid 3:1 ratio 
and subsequently stained with 0.5% crystal violet for 60 min at room 
temperature. The numbers of colonies containing more than 50 cells were 
counted. 
5. RNA sequencing 
Total RNA was extracted using the RNeasy mini kit (Qiagen, Valencia, CA, 
USA). The quantity and quality of the total RNA were evaluated using RNA 
electropherograms (Bio-Rad Experion, Hercules, CA, USA) and the RNA 
quality was assessed based on the RNA quality indicator (RQI). The total 
RNA from each sample with a RQI value of 8.0 or higher was used. The 
resulting mRNA samples were processed for the sequencing libraries using 
the Illumina TruSeq Stranded mRNA sample preparation kit (Illumina, San 
Diego, CA, USA) according to the manufacturer’s protocols. RNA 
sequencing was performed using the Illumina HiSeq 2500 to generate non-
directional, paired-end 100-base-pair reads. Quality-filtered reads were 
mapped to the human reference genome sequences, hg19 (UCSC Genome 
8Bioinformatics, https://genome.ucsc.edu) using tophat2 
(http://ccb.jhu.edu/software/tophat). The relative transcript abundance was 
estimated by counting the fragments per kilobase of exon model per million 
mapped sequence reads (FPKM) and differential expressed genes were 
evaluated using cufflinks package (http://cufflinks.cbcb.umd.edu). The 
significantly overlapping pathways and Gene Ontology categories with 
differential expressed genes were analyzed using DAVID 
(http://david.abcc.ncifcrf.gov).
6. Western blot analysis 
Total cell lysates were prepared by lysing the cells in RIPA buffer (Thermo 
Scientific, Rockford, IL, USA), which contains 0.01% of a protease and 
phosphatase inhibitor cocktail (Thermo Scientific). Equal amounts (50 µg) of 
total proteins were fractionated through SDS-PAGE on a 10% gel and 
transferred to PVDF membranes (Roche, Basel, Switzerland). The membrane 
was blocked with 5% milk/Tris-buffered saline plus Tween 20 (TBST) and 
incubated with primary antibodies against human E2F1 (sc-251), p53 (sc-6243) 
and PARP-1 (sc-8007) (all from Santa Cruz Biotechnology, Santa Cruz, CA, 
USA). HRP goat anti-mouse IgG (Santa Cruz) and HRP goat anti-rabbit IgG 
(Cell signaling, Danvers, MA, USA) were used for secondary antibody. 
Immunoreactive bands were visualized using a LAS-3000 Imager (Fujifilm
Corporation, Tokyo, Japan). Equal loading was assessed after probing the 
same membrane with β-actin antibody (Santa Cruz). 
97. Detection of CD133+ glioma stem cells
The cells were harvested through enzymatic dissociation and resuspended 
in PBS supplemented with 2% FBS. To analyze the cell surface markers, 
1×106 cells were labeled with a allophycocyanin (APC)-conjugated anti-
CD133 antibody (clone 293C3, Miltenyi Biotech, Bergisch Gladbach, 
Germany) for 30 min at 4℃. APC-conjugated mouse IgG2b isotype control 
antibody was used to exclude nonspecific binding. The cells were washed 
three times with PBS and subsequently analyzed through FACSVerse flow 
cytometry (BD Bioscience).
8. Cell migration assay
A scratch wound-healing assay was performed to assess cell migration. The 
cells were seeded at 5×105 in 6-well plates and incubated for 24 h until 
reaching the appropriate confluence on the day of experiment. An artificial 
scratch wound was made using a sterile 200-μl pipette tip on the cell 
monolayer. After the scraping, the floating cells were washed with PBS and 
fresh medium was added. Differences in the wound width were 
microscopically visualized at ×40 magnification at three time points (0, 9 and 
18 h).
9. Sphere forming assay 
After the 3rd mEHT, the single cell suspension was diluted to a 
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concentration of 2×104 cell/ml in serum-free DMEM/F12 medium (Invitrogen, 
Carlsbad, CA, USA) supplemented with 20 ng/ml recombinant epidermal 
growth factor (EGF) (Invitrogen), 20 ng/ml basic fibroblast growth factor 
(bFGF) (Invitrogen), and 1X B27 supplement (Invitrogen) and subsequently 
plated onto ultra-low attachment 24-well plates (Corning). After 5 days of 
culture, sphere formation was microscopically evaluated using NIS element 
BR software Version 4.2 to count the number of spheres greater than or equal 
to 40 μm in diameter, and to measure the size of each sphere. 
10. Statistical analysis
Statistical comparisons were conducted using Student’s t-test with equal 
variance, Bootstrap t-test with 10,000 random repetitions or Poisson 
Generalized Linear Model. All data are shown as the means ± SEM. Analyses 
were conducted using R statistical software (v. 3.0.1). P values ≤ 0.05 (*) and 
≤ 0.01 (**) were considered statistically significant. 
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III. RESULTS
1. Electro-hyperthermia inhibits proliferation and induces apoptosis in 
glioma cells 
As shown in Figure 1, the temperature within a Treatment Cup (a cup 
containing culture medium and a slide coated with cells) increased to 42℃
within 8 min and remained in a range of 42-43℃ during heating using a 
LAB-EHY100 device, which controls RF power. To examine the therapeutic 
efficacy of mEHT, two glioma cell lines, U87-MG and A172, were treated for 
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1 h with mEHT three times at a 2-day interval, and the cell growth was 
determined using an MTS assay. 
Figure 2. mEHT reduces viability and long-term colony formation in glioma 
cells. (A) Representative light microscopy images of U87-MG and A172 cells 
at 72 h after treating three times with mEHT. Scale bar, 100 µm. (B) 
Measurement of cell viability in U87-MG and A172 cells at 72 h after the third 
mEHT treatment. The data represent three independent experiments. NT, no 
treatment. **, P < 0.01, *, P < 0.05 by Bootstrap t-test. (C) Observation of 
long-term colony formation using a clonogenic assay at 12 days after the 3
rd
mEHT treatment. The data represent three independent experiments. **, P < 
0.01 using the Poisson Generalized Linear Model.
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The mEHT treatments decreased cell proliferation more than 70% and 45% 
in U87-MG and A172 cells, respectively (Figure 2A-2B). This treatment 
condition was applied to all subsequent in vitro studies. Consistent with the 
results of the short-term phenotypic assay, mEHT was also effective in 
inhibiting long-term colony formation (Figure 2C). The magnitudes of the 
reduction in clonogenicity in response to mETH were similar to the growth 
inhibition, as determined using the MTS assay (Figure 2B). 
Figure 3. mEHT induces apoptosis in glioma cells.
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The growth inhibition of mEHT-treated glioma cells might reflect the strong 
induction of apoptosis as measured through the detection of the apoptotic 
marker Annexin V using FACS (Figure 3A). Namely, at 72 h after the 3rd
mEHT treatment, the percentage of late-apoptotic (Q2 region) plus early-
apoptotic cell populations (Q3) in U87-MG and A172 cells increased 80% and 
50%, respectively. To confirm the apoptotic induction through mEHT, we 
conducted an ELISA assay to detect the denatured single-stranded DNA 
formed in apoptotic cells but not in the necrotic cells or cells with DNA 
breaks. The results showed that mEHT significantly increased the apoptotic 
cell population in U87-MG and A172 cells approximately 2.2- and 1.4-fold, 
respectively, at 48 h after the 3rd mETH (Fig. 3B). To further observe the onset 
of apoptosis through mEHT, U87-MG and A172 cells were assayed through 
FACS analysis at various time points (24, 48 and 72 h) after the 3rd mEHT. As 
(A) Detection of the apoptotic cell population through FACS analysis with 
the intensity of apoptotic marker Annexin V at 72 h after the 3
rd
mEHT
treatment. (B) Detection of apoptosis at 48 h after the 3
rd
mEHT treatment 
using the ApoStrand ELISA Apoptosis Detection Kit. The data represent 
three independent experiments. NT, no treatment. **, P < 0.01 by Bootstrap 
t-test. (C-D) Detection of the apoptotic cell population through FACS 
analysis based on the intensity of the apoptotic marker Annexin V in U87-
MG (C) and A172 (D) cells at 24, 48 and 72 h after the 3
rd
mEHT treatment. 
The data represent duplicate experiments. **, P < 0.01 by Student’s t-test 
with equal variance. 
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shown in Figure 3C and 3D, mEHT induced both necrosis and apoptosis at all 
time points examined in glioma cells. However, this treatment mainly 
increased the number of apoptotic cells at 24 h, the earliest time point 
examined. These data suggest that mEHT treatments induce apoptosis in 
human glioma cells. 
16
2. The molecular mechanisms underlying the growth inhibitory effects of 
electro-hyperthermia
17
To determine the molecular basis of the observed growth inhibition through
mEHT, we compared the global gene expression profiles of mEHT-treated 
U87-MG and A172 cells to those of sham-treated control cells using next-
generation RNA sequencing. The paired-end mRNA sequencing analysis 
revealed that mEHT led to the up- and down-regulation of 684 genes in U87-
MG and 488 genes in A172 cells (Figure 4A). Comparing these two gene sets 
to identify a common anti-cancer mechanism revealed a statistically 
significant overlap of 34 genes (19 genes up- and 15 genes down-regulated) 
defined using a Bootstrap t-test with 10,000 repetitions and at least a 2-fold 
change (P < 0.001) (Figure 4B), and this effect is considered a common 
mEHT molecular signature in glioma cells. Ingenuity pathway analysis (IPA) 
Figure 4. Transcriptomic analysis of gene expression by RNA sequencing 
following the mEHT treatment. (A) Venn diagrams representing the number 
of mRNA transcripts up- or down-regulated in U87-MG or A172 cells after 
mEHT treatment. (B) A heat map of the 34 commonly deregulated genes in 
U87-MG and A172 cells after normalization to the corresponding sham-
treated cells (10,000 repetitions in Bootstrap ANOVA with contrast tests 
and a threshold cut-off of 2-fold change, **P < 0.001, red (induced) and 
green (repressed), log2-based scale). (C, D) Two putative top networks with 
high scores (>19) strongly associated with E2F1 (C) and ubiquitin C (UBC)
(D) based on Fisher’s exact test (p value < 10-19), indicating a high 
probability of biological interactions. Up- and down-regulated genes are 
shown in red and green, respectively. The genes shown in gray are 
associated with the regulated genes.
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showed that the 34 mRNA transcripts were functionally enriched in the top 
two networks shown in Figures 4C and 4D. Consistent with phenotypic 
changes, mEHT coordinately impacts a restricted number of defined 
oncogenic pathways acting in concert to decrease cell proliferation and induce 
apoptosis, providing a rationale for the therapeutic use of mEHT in glioma. 
Consistently, the expression levels of E2F1 and CPSF2 involved in pro-
apoptotic activity and growth suppression were upregulated, whereas two key 
regulators of cell growth, PSAT1 and ADAR, were repressed. In particular, 
the transcription factor adenovirus E2 promoter-binding factor (E2F) 1 gene, 
which is functionally involved in exerting apoptotic progression,13-15 was 
upregulated through after mEHT treatment and this process was positioned at 
a central region of interactive top network 1 (Figure 4C). 
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Subsequent Western blot analysis confirmed the increase of E2F1 protein 
with a concomitant increase of p53 tumor suppressor and decrease of PARP-1, 
a nuclear enzyme essential for genomic stability and chromatin remodeling in 
both U87-MG and A172 cell lines (Figure 5). Next, to determine whether 
E2F1-mediated apoptotic induction was mEHT-specific, we assessed the 
levels of E2F1, p53 and PARP-1 in glioma cells heated three times for 1 h 
with a two-day interval in a water bath with 42℃, compared with mEHT-
treated cells. As shown in Figure 5 (right panel), while heat stress upregulated 
p53 and downregulated PARP-1 expression, it did not change the levels of 
E2F1. This finding identifies E2F1-mediated apoptosis as an essential and 
common mechanism of growth suppression in mEHT-treated glioma cells. 
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3. Electro-hyperthermia inhibits glioma growth in vivo
We next investigated whether mEHT could suppress glioma tumorigenicity. 
To test the therapeutic efficacy of mEHT in vivo, we used a U87-MG 
xenograft in nude mice. All mice received subcutaneous injection of 1×107 
U87-MG glioma cells in the right flank and on day 9 when tumors had 
reached an average volume of ~100-120 mm3, and the mice were randomly 
assigned to either mEHT treatment or control groups. Electro-hyperthermia 
21
was directly applied 7 times on the surface of each tumor on 9, 11, 13, 15, 17, 
19 and 21 days after the glioma cell transplantation, and tumor growth was 
monitored using a caliper ruler. The results showed that mEHT treatments 
significantly suppressed the growth of human glioma xenografts (Figure 6) 
(*P < 0.05). 
4. Electro-hyperthermia inhibits the maintenance of glioma stem cells
Increasing evidence has indicated that a small fraction of cancer cells are 
CSCs, responsible for tumor persistence and relapse, metastasis, 
chemoresistance and radioresistance. As shown in Figure 4B, we observed 
that mEHT downregulated the adenosine deaminase acting on dsRNA (ADAR, 
also known as ADAR1) and upregulated the cleavage and polyadenylation 
specificity factor subunit 2 (CPSF2), both of which are functionally associated 
with CSC biology. Recent studies have demonstrated that ADAR1 knockdown 
impaired the in vivo self-renewal capacity of chronic myeloid leukemia 
progenitors,16 and the loss of CPSF2 expression was associated with an 
increase in thyroid cancer invasion and the CSC population, particularly 
upregulating the level of a CSC marker CD133.17 It has also been reported 
that glioma CSCs express CD133 and grow in spheroid patterns in special 
growth medium.18, 19 Thus, we examined whether mEHT could affect the 
maintenance of glioma stem cells. To accomplish this, we first measured the 
22
change in the percentage of CSC portion after the 3rd mEHT treatment. Next, 
20,000 U87-MG cells treated with mEHT in the same way were plated on a 
24-well plate and cultured for 5 days to observe the change in sphere forming 
capacity by counting the number of spheres greater than or equal to 40 μm in 
diameter and measuring the size of each sphere. 
23
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As expected, mEHT eliminated the CD133+ U87-MG cell population 
approximately 80% (Figure 7A) and significantly decreased cancer stemness 
by reducing both the number (48 spheres formed in no treatment vs. 20 in 
mEHT) and the average size of spheres (Figure 7B) when compared with 
control treatments. In addition, the scratch would-healing test showed that 
mEHT suppressed U87-MG cell migration, indicating the decreased stemness 
of the cells (Figure 7C). These data indicate that mEHT could prevent glioma 
recurrence through the elimination of CSCs in the brain tumor 
microenvironment.
25
IV. DISCUSSION
mEHT concentrates the modulated radiofrequency current to intercellular 
electrolytes, generating a temperature gradient between the inside and outside of 
cells.5 This gradient destroys the tumor cell membrane, leading to apoptosis or 
necrosis.6, 20, 21 Numerous clinical studies have demonstrated that mEHT is 
effective for controlling advanced primary and metastatic malignancies, such as 
bone (metastatic), breast cancer and malignant glioma.10, 22-24 However, the 
molecular mechanism underlying the induction of cancer cell death through 
mEHT remains unclear. In the present study, mEHT induced extensive apoptosis 
in both U87-MG and A172 glioma cell lines (Fig. 3). The phenotypic changes 
induced through mEHT were associated with the coordinated and common dysre
gulation of 34 genes (Fig. 4), as assessed through a global transcriptomic 
analysis for RNA sequencing, including the upregulation of E2F1, a transcription 
factor that plays a pivotal role in accelerating apoptotic progression.13-15 Both the 
p53 and E2F1 are defective in almost all types of tumors,25 while U87MG glioma 
cell line is known to have wild type p53.26 A previous study showed that 
overexpression of E2F1 is associated with loss of cell viability and E2F1-
mediated glioma cell death is caused by apoptosis.27 One study prior to that 
reported the transfer of exogenous wild-type p53 cDNA did not cause apoptosis 
in cells that express endogenous wild-type p53, which might be from the 
overexpression of p21, the negative regulator of the cell cycle.26 Based on them, 
the upregulation of E2F1 paralleling the increase of p53 tumor suppressor, a 
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downstream effector of E2F1, and decrease of PARP-1 (Fig. 5A), seems to be 
providing a mechanism for the mEHT-mediated inhibition of cell cycle 
progression and induction of apoptosis in glioma cells. This finding is consistent 
with the recent studies showing that the stabilization of p53 drives apoptosis via 
the Rb/E2F1 signaling pathway,15 and the attenuation of PARP-1 increases E2F1 
transactivation to inhibit cell cycle progression.14 The E2F1-mediated apoptosis 
induced through mEHT might be an essential molecular mechanism explaining 
the clinical efficacy of mEHT and therefore requires thorough investigation.
Glioblastoma is the most common primary brain tumor, with a high invasive 
nature. CSCs in glioblastoma are radioresistant and chemoresistant. Thus, 
targeting the CSCs might be an efficient therapy to prevent tumor recurrence 
after treatment.28, 29 A previous study reported that the conventional hyperthermia 
effectively reduced a portion of breast CSCs in both single treatment and 
combinatory treatment with metformin.30 Through whole-genome RNA sequence 
analysis, we observed in this study that the inhibition of glioma cell growth 
through mEHT is associated with the downregulation of ADAR1 transcripts, 
which was functionally validated to increase self-renewal.16 In addition, the 
CPSF2 gene, upregulated through mEHT treatment, was correlated with 
increased CSC invasion when decreased in expression.17 These molecular clues 
prompted us to determine whether mEHT could therapeutically eliminate glioma 
stem cells. The results of various CSC assays revealed that mEHT showed 
remarkable efficacy in eliminating the CD133+ glioma stem cell population and 
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decreasing sphere formation and migration. These findings suggest that mEHT 
could be a novel treatment option for preventing glioma recurrence. 
V. CONCLUSION
In conclusion, in the present study using human glioma cell lines, we 
showed that mEHT induced the inhibition of cell proliferation and 
clonogenicity, induced apoptosis in vitro, and suppressed the growth of a 
glioma xenograft in nude mice. The anti-tumorigenic effects of mEHT might 
reflect the upregulation of the E2F1 transcriptional factor. mEHT also 
eliminated cancer stem cells or stem-cells like glioma cells, indicating that 
mEHT might be effective to prevent the recurrence and metastasis of tumors.
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ABSTRACT (IN KOREAN)
전기적 온열치료의 신경아교종에 대한 항암효과 기전으로서의
E2F1 매개 세포자멸사
<지도교수 이 창 걸>
연세대학교 대학원 의학과
차 지 혜
목적: Modulated electro-hyperthermia (mEHT)는 고주파를
이용하여 열을 발생시키는 심부 전기적 온열치료의 한
방법으로, 신경아교종을 포함한 여러 종양에서 현저한 치료
효과를 보임이 보고되어 왔다. 본 연구의 목적은 mEHT를 시행
받은 암세포의 표현형 변화와 그 분자기전을 밝히는 데 있다.
재료 및 방법: 신경아교종 세포주 U87-MG와 A172에 mEHT 
(42℃/60분)를 2일 간격으로 3회 시행하였고 성장 억제
확인을 위해 MTS와 FACS, 현미경적 분석을 시행하였다. 
mEHT가 일으키는 분자기전 파악을 위해 RNA 서열 결정을
시행하여 mEHT에 의한 유전자 발현 변화를 확인하였다. 
mEHT의 생체내 작용 확인을 위해 누드생쥐에 U87-MG 세포주의
이종이식실험을 시행하였다. 
결과: mEHT는 세포자멸사를 강하게 유도함으로써 신경아교종
세포의 증식을 억제했다. 전사체 분석을 통해 mEHT 시행 후의
증식 억제 효과가, E2F1와 CPSF2의 상향조절과 ADAR과
PSAT1의 하향조절을 비롯한 분자변화에 기인함을 확인하였다. 
후속적으로 단백질흡입법을 시행하여 mEHT가 E2F1, p53을
증가시키고 PARP-1을 감소시키는 것을 확인했으며, 이는
세포자멸사를 촉진하는 신호전달체계와의 연관성을 시사하는
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결과이다. 또한 누드생쥐 이종이식실험에서도 mEHT는
신경아교종의 증식을 효과적으로 억제하였으며, CD133+
신경아교종 줄기세포의 비율을 크게 감소시키고 종양세포
이동과 구 형성을 억제하는 작용을 나타냈다.
결론: mEHT는 E2F1이 매개하는 세포자멸사의 촉진을 기전으로
하여 신경아교종 세포의 증식과 세포 이동을 억제하는 것으로
생각되며, 뇌종양의 치료에 효율적으로 적용할 수 있을
것으로 생각된다.
---------------------------------------------------------
핵심되는 말: 전기적 온열치료, 신경아교종, E2F1, 세포자멸
사, 종양줄기세포
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